Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

Few therapeutic options exist for the highly aggressive triple negative breast cancers (TNBCs). In this study, we report that a contextual synthetic lethality can be achieved both in vitro and in vivo with combined EGFR and PARP inhibition with lapatinib and ABT-888, respectively. The mechanism invo...

Full description

Bibliographic Details
Main Authors:	Nowsheen, Somaira, Cooper, Tiffiny, Stanley, Jennifer A., Yang, Eddy S.
Format:	Online
Language:	English
Published:	Public Library of Science 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469581/

Similar Items

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
by: Bajrami, Ilirjana, et al.
Published: (2012)

Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
by: McLellan, Jessica L., et al.
Published: (2012)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
by: YI, YONG WEON, et al.
Published: (2015)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
by: Horiuchi, Dai, et al.
Published: (2012)

Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
by: Inoue, Satoshi, et al.
Published: (2012)

Targeting EGFR in Triple Negative Breast Cancer
by: Ueno, Naoto T., et al.
Published: (2011)

Targeting EGFR in Triple Negative Breast Cancer
by: Naoto T. Ueno, Dongwei Zhang
Published: (2011-01-01)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
by: Lovato, Amanda, et al.
Published: (2012)

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
by: Mendes-Pereira, Ana M, et al.
Published: (2009)

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
by: Mohammad Asim, et al.
Published: (2017-08-01)

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
by: Murata, Stephen, et al.
Published: (2016)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
by: Gautam, Prson, et al.
Published: (2016)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
by: Ha, Kyungsoo, et al.
Published: (2014)

Emerging Roles of Glycogen Synthase Kinase 3 in the Treatment of Brain Tumors
by: Mills, Caroline N., et al.
Published: (2011)

Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer
by: Sood, Neelam, et al.
Published: (2014)

Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR
by: Wang, Yuan-Liang, et al.
Published: (2015)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
by: Secq, V, et al.
Published: (2014)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
by: Yi, Yong Weon, et al.
Published: (2013)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
by: Aleksandra Simiczyjew, et al.
Published: (2018-09-01)

Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype
by: He, Qing, et al.
Published: (2016)

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
by: Luo, Jiayan, et al.
Published: (2016)

Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
by: Boerner, Julie L., et al.
Published: (2015)

In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment
by: Li, Jian, et al.
Published: (2016)

The Role of Protein Interactions in Mediating Essentiality and Synthetic Lethality
by: Talavera, David, et al.
Published: (2013)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
by: Thompson, Jordan M., et al.
Published: (2015)

Triple-Negative Breast Cancer
by: Chu, Quyen D., et al.
Published: (2012)

DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma
by: Weaver, Alice N., et al.
Published: (2015)

Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer
by: Nowsheen, Somaira, et al.
Published: (2011)

MicroRNAs Expression in Triple Negative vs Non Triple Negative Breast Cancer in Tunisia: Interaction with Clinical Outcome
by: Medimegh, Imen, et al.
Published: (2014)

PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
by: Swindall, Amanda F., et al.
Published: (2013)

DNA repair and synthetic lethality
by: Guo, Gong-she, et al.
Published: (2011)

Triple Negative Breast Cancer – An Overview
by: Aysola, Kartik, et al.
Published: (2013)

VEGF-A, VEGF-C, VEGF-R2, EGFR and HER2 in serum plus EGFR in tissue of patients with triple-negative breast cancer
by: Iosifidou, R, et al.
Published: (2009)

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
by: Teng, Yvonne Hui-Fang, et al.
Published: (2011)

Regulation of IMP3 by EGFR Signaling and Repression by ERβ: Implications for Triple Negative Breast Cancer
by: Samanta, Sanjoy, et al.
Published: (2012)

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
by: El Guerrab, Abderrahim, et al.
Published: (2011)

Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides
by: Yu, Yung-Luen, et al.
Published: (2013)

Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
by: Mehta, Rajeshwari, et al.
Published: (2013)

MUC4 Overexpression Augments Cell Migration and Metastasis through EGFR Family Proteins in Triple Negative Breast Cancer Cells
by: Mukhopadhyay, Partha, et al.
Published: (2013)

Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women
by: Kanapathy Pillai, Shant Kishen, et al.
Published: (2012)